Biotech Overbought Stocks: Illumina (NASDAQ:ILMN), Northwest Biotherapeutics (NASDAQ:NWBO), Arrowhead Research (NASDAQ:ARWR), Albany Molecular Research, (NASDAQ:AMRI)

Illumina, Inc. (NASDAQ:ILMN) announced that Science for Life Laboratory (SciLifeLab) in Sweden has joined the Illumina Genome Network (IGN) to provide researchers with broader access to Illumina’s whole genome sequencing technology. SciLifeLab is the first IGN partner in Europe and will initiate a national large-scale population sequencing program seeking to identify genetic causes of human diseases. Illumina, Inc. (NASDAQ:ILMN) stock opened at $175.26 in last trading session, and closed at $178.53, trading in the range of $174.23 – $180.74.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) average recommendation is buy with average Target Price of $5.00. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares closed at $6.93 on last trade day, by gaining 9.48%. Stock 52 week range is $3.10 – $7.00. Company’s market capitalization is $300.79 million.

Arrowhead Research Corporation (NASDAQ: ARWR) a biopharmaceutical company developing targeted RNAi therapeutics announced that on February 24 2014 it closed the previously announced underwritten offering of 6325000 shares of common stock which included shares issued upon the exercise in full by the underwriters of their option to purchase 825000 additional shares. The offering was priced at $18.95 per share and the company received gross proceeds of approximately $120 million before deducting underwriting discounts commissions and other offering expenses payable by the company. Jefferies LLC Barclays Capital Inc. and Deutsche Bank Securities acted as joint book-runners for the offering. Piper Jaffray & Co. acted as lead manager for the offering and Trout Capital acted as a financial advisor to the Company. Arrowhead Research Corp (NASDAQ:ARWR) stock decreased -0.22% and finished the last session at $22.40. The EPS of the stock remained -1.27. Company’s market capitalization is $888.99 billion.

McLean Capital Management upgraded shares of Albany Molecular Research (NASDAQ:AMRI) from a neutral rating to a buy rating in a research report sent to investors on Friday morning, StockRatingsNetwork reports. Albany Molecular Research, Inc. (NASDAQ:AMRI) stock opened at $14.99 in last trading session and closed at $15.03. The 52 week range of the stock is $7.75 – $15.22 and the day range was $14.53 – $15.22.